NCT06894030

Brief Summary

The goal of this clinical trial is to learn if cognitive cueing (eg., prompting individuals to think about taking big-long steps while walking), either as a stand- alone intervention or combined with a personalized gait training video, can improve gait (walking), mobility, and balance confidence for individuals with Parkinson's Disease. The main questions it aims to answer are:

  • Complete walking trials on an instrumented mat that records data on their walking ability. These trials will be undertaken without a cognitive cue and while participants mentally rehearse a series of 3 cognitive cues (Take big long steps; Walk heel-toe; Stand up straight).
  • Be informed about which of the 3 cues best improved their walking and will receive a personalized gait training video for at home practice.
  • Complete online surveys that ask questions about their Parkinson's Disease, mobility, balance confidence quality of life and conscious attention to gait.
  • Visit the research facility 3 to 4 times during the study to have their gait (walking), mobility, balance confidence, quality of life and conscious attention to gait assessed and reassessed.
  • Practice both with and without their personalized video at home and keep a diary to record their practice sessions
  • Participate in a brief interview to discuss their experiences with the training and their perceptions of the effectiveness of cognitive cues and video-recorded feedback

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
39mo left

Started Apr 2025

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress26%
Apr 2025Aug 2029

First Submitted

Initial submission to the registry

March 11, 2025

Completed
14 days until next milestone

First Posted

Study publicly available on registry

March 25, 2025

Completed
7 days until next milestone

Study Start

First participant enrolled

April 1, 2025

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2028

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2029

Last Updated

March 25, 2025

Status Verified

March 1, 2025

Enrollment Period

3.3 years

First QC Date

March 11, 2025

Last Update Submit

March 18, 2025

Conditions

Keywords

GaitCueingBalanceMobility

Outcome Measures

Primary Outcomes (9)

  • Mean Stride Length

    Mean of stride length measured in centimeters (cm).

    From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

  • Variability iin Stride Length

    Coefficient of variation in stride length.

    From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

  • Mean of Stride Width

    Mean of stride width measured in centimeters (cm).

    From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

  • Variability in Stride Width

    Coefficient of variation in stride width.

    From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

  • Mean of Stride Velocity

    Mean of stride velocity measured in centimeters per second-squared (cm/s\^2).

    From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

  • Variability in Sride Velocity

    Coefficient of variation in stride velocity.

    From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

  • Mean of Double Support Time

    Mean double support time measured as a proportion (0-1). This is the proportion of a gait cycle spent with two feet on the ground.

    From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

  • Variability in Double Support Time

    Coefficient of variation in double support time

    From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

  • Timed Up and Go (TUG)

    Timed test of functional mobility where participants are recorded on the number of seconds it takes to stand up from a chair, walk 10ft, turn around, walk back 10ft, and sit back in the chair. Longer times suggest lower functional mobility.

    From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

Secondary Outcomes (4)

  • Activities-specific Balance Confidence Scale (ABC)

    From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

  • Gait-Specific Attentional Profile (G-SAP)

    From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

  • Parkinson's Disease Quality of Life Questionnaire (PDQ-39)

    From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

  • Standardized Mini Mental State Examination (SMMSE)

    At baseline only

Study Arms (2)

Video Start

EXPERIMENTAL
Behavioral: Gait Training VideoBehavioral: Cognitive Cue

Video Delay

EXPERIMENTAL
Behavioral: Gait Training VideoBehavioral: Cognitive Cue

Interventions

Personalized gait training videos featuring cued and non-cued gait for participants

Video DelayVideo Start
Cognitive CueBEHAVIORAL

A verbal cue to be mentally rehearsed by each participant

Video DelayVideo Start

Eligibility Criteria

Age40 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Be diagnosed with Parkinson's Disease
  • Be fluent in English
  • Be able to walk independently and without a walking aid for at least 10 minutes
  • Have no other cognitive or neurological impairments (e.g., brain tumours, recent concussion, stroke, brain injury)

You may not qualify if:

  • Deep Brain Stimulation (DBS) implant
  • Standardized Mini Mental State Examination (SMMSE) score less than 24

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre for Brain and Mind, Western University

London, Ontario, N6A 3K7, Canada

Location

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Central Study Contacts

Jeffrey Holmes

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
CROSSOVER
Model Details: The Video Start group will receive their gait training video once the intervention begins. The Video Delay group will receive their gait training video after a 4-week delay.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor, School of Occupational Therapy

Study Record Dates

First Submitted

March 11, 2025

First Posted

March 25, 2025

Study Start

April 1, 2025

Primary Completion (Estimated)

August 1, 2028

Study Completion (Estimated)

August 1, 2029

Last Updated

March 25, 2025

Record last verified: 2025-03

Locations